Appointment dossier — Ovarian Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Cancer
- Olaparib — Human evidence · 3 positive · PMID 37592269, 33743851, 30345884, 39013199
- Bevacizumab — Human evidence · 2 positive / 2 negative-mixed · PMID 38872480, 22529265, 39013199, 36603894
- Relacorilant — Human evidence · 2 positive / 1 negative-mixed · PMID 42334771, 40473448, 39032926, 37364223
- Cisplatin — Human evidence · 1 positive / 1 negative-mixed · PMID 39549720, 39013199, 22330607
- Mirvetuximab Soravtansine — Human evidence · 1 positive / 2 negative-mixed · PMID 40508029, 39631181, 30379722
- Paclitaxel — Human evidence · 1 positive / 2 negative-mixed · PMID 37592269, 40010134, 39013199, 22591426
- Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
- Rucaparib — Human evidence · 0 positive / 1 negative-mixed · PMID 39266137, 39013199, 34593565
- Carboplatin — Review evidence · 1 positive · PMID 37592269, 39013199
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Genistein — Review evidence · 1 positive · PMID 42133114
- Anastrozole — Review evidence · 0 positive · PMID 39013199
- Gemcitabine — Review evidence · 0 positive · PMID 39013199, 33917230
- Liposomal Doxorubicin — Review evidence · 0 positive · PMID 39013199
- Niraparib †Rx — Review evidence · 0 positive · PMID 39013199
- Tamoxifen — Review evidence · 0 positive · PMID 39013199
- Topotecan — Review evidence · 0 positive · PMID 39013199
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05659381 · Phase 3 — Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (United States)
- NCT05961124 · Phase 2 — Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer (Canada)
- NCT03878849 · Phase 2 — Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer (United States)
- NCT06690775 · Phase 2 — CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (United States)
- NCT06971744 · Phase 2 — Autophagy Maintenance (AUTOMAIN) (United States)
- NCT06687070 · Phase 1 — APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST (China)
- NCT06778863 · Phase 1 — A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation (United States)
- NCT04282044 · Phase 1 — Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (United States)
- NCT05427487 · Phase 1 — Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (Australia)
- NCT06276491 · Phase 1 — Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (United States)
- NCT05080946 · Early Phase 1 — Using Aspirin to Improve Immunological Features of Ovarian Tumors (United States)
- NCT06071286 — SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS (Italy)
- NCT04284969 — PROADAPT-ovary/EWOC-2 (France)
- NCT00539162 — Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women (United States)
- NCT04251052 — A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (United States)
- NCT05984875 — The Immune Landscape of Epithelial Ovarian Cancer (Switzerland)
- NCT06458712 · Phase 1 — Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies (United States)
- NCT04804007 · Phase 2 — Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT (United States)
Most-relevant first: trials that name Ovarian Cancer, then broader trials you may still qualify for. 777 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Niraparib †Rx × CYP1A2 inhibitors (high-stakes) — Monitor (low)
- Niraparib †Rx × P-gp substrates (high-stakes) — Monitor (low)
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Niraparib †Rx × Bevacizumab — Synergize (low)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Olaparib has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Bevacizumab has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Relacorilant has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05659381), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?